BACE1 and Alzheimer disease: These observations provide strong support for continued efforts to target BACE1 therapeutically in AD (Hampel et al, 2021; McDade et al, 2021), although dosing and timing of treatment relative to disease progression will be critical, with reports suggesting that treatment will be more efficient early in disease before heavy plaque deposition (McDade et al, 2021).